SLC22A13 has so far been determined to be a urate transporter by in vitro analysis, and studies have uncovered that dysfunctional variant of SLC22A13 reduce both gout risk and serum uric acid levels, suggesting that SLC22A13 is physiologically implicated in uric acid reabsorption in the human kidney [52]. Here, SLC2A9 is linked to gout.